

Hayrettin Tumani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3184121/publications.pdf>

Version: 2024-02-01

174
papers

11,101
citations

25034

57
h-index

34986

98
g-index

187
all docs

187
docs citations

187
times ranked

11781
citing authors

#	ARTICLE	IF	CITATIONS
1	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , 2009, 73, 1914-1922.	1.1	653
2	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	7.2	593
3	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.8	354
4	Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldtâ€“Jakob disease. <i>Neuroscience Letters</i> , 1997, 225, 210-212.	2.1	332
5	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
6	Guillainâ€“BarrÃ© syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. <i>Journal of Neurology</i> , 2021, 268, 1133-1170.	3.6	286
7	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	3.0	249
8	Axonal damage markers in cerebrospinal fluid are increased in ALS. <i>Neurology</i> , 2006, 66, 852-856.	1.1	236
9	Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. <i>Neurology</i> , 1994, 44, 1523-1523.	1.1	223
10	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2015-311387.	1.9	207
11	Blood GFAP as an emerging biomarker in brain and spinal cord disorders. <i>Nature Reviews Neurology</i> , 2022, 18, 158-172.	10.1	205
12	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.4	197
13	The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. <i>Nature Reviews Neurology</i> , 2013, 9, 267-276.	10.1	181
14	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 157-164.	1.9	174
15	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.0	173
16	Serum GFAP as a biomarker for disease severity in multiple sclerosis. <i>Scientific Reports</i> , 2018, 8, 14798.	3.3	164
17	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1407-1416.	0.8	152
18	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015, 138, 918-931.	7.6	147

#	ARTICLE	IF	CITATIONS
19	Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7864-7869.	7.1	145
20	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2016, 2, e1501678.	10.3	133
21	The cerebrospinal fluid and barriers – anatomic and physiologic considerations. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 21-32.	1.8	127
22	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 639-647.	1.9	123
23	The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS). PLoS ONE, 2010, 5, e11986.	2.5	122
24	Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 143-148.	3.0	106
25	IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome. PLoS ONE, 2009, 4, e7638.	2.5	106
26	Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiology of Disease, 2009, 35, 117-127.	4.4	104
27	Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain, 2013, 136, 1048-1066.	7.6	100
28	Isolated blood–cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. Journal of Neurology, 2005, 252, 1067-1073.	3.6	98
29	Tau protein in cerebrospinal fluid (CSF): a blood–CSF barrier related evaluation in patients with various neurological diseases. Neuroscience Letters, 2001, 300, 95-98.	2.1	91
30	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
31	Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neuroscience Letters, 2003, 353, 57-60.	2.1	87
32	Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. Multiple Sclerosis Journal, 2016, 22, 502-510.	3.0	87
33	Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. Frontiers in Neurology, 2019, 10, 280.	2.4	87
34	The chemokine CXCL13 in acute neuroborreliosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 929-933.	1.9	84
35	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Journal of Neuroinflammation, 2022, 19, 19.	7.2	82
36	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 1-10.	2.1	81

#	ARTICLE	IF	CITATIONS
37	Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. <i>Journal of Neuroimmunology</i> , 2000, 110, 244-251.	2.3	80
38	Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1134-1136.	1.9	78
39	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1036-1044.	3.0	78
40	Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 479-494.	3.1	77
41	Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e88680.	2.5	75
42	Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 541-551.	2.6	74
43	EFNS guidelines on disease-specific CSF investigations. <i>European Journal of Neurology</i> , 2009, 16, 760.	3.3	73
44	Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1209-1212.	3.0	69
45	Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. <i>Brain</i> , 2014, 137, 2703-2714.	7.6	69
46	Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases. <i>International Journal of Molecular Sciences</i> , 2015, 16, 14669-14676.	4.1	69
47	Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. <i>Epilepsy Research</i> , 1999, 36, 75-82.	1.6	68
48	Neurofilament heavy chain NfH ^{SMI35} in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. <i>Movement Disorders</i> , 2006, 21, 2224-2227.	3.9	68
49	?-Trace protein in cerebrospinal fluid: A blood-CSF barrier-related evaluation in neurological diseases. <i>Annals of Neurology</i> , 1998, 44, 882-889.	5.3	67
50	Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. <i>Journal of Neurology</i> , 2011, 258, 1034-1041.	3.6	67
51	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	6.1	67
52	Cerebrospinal fluid proteome profile in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 840-849.	3.0	66
53	Glutamine Synthetase in Cerebrospinal Fluid, Serum, and Brain. <i>Archives of Neurology</i> , 1999, 56, 1241.	4.5	64
54	Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1 ^β . <i>BMC Neurology</i> , 2016, 16, 185.	1.8	64

#	ARTICLE	IF	CITATIONS
55	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 344-350.	1.7	62
56	Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 261-265.	3.0	60
57	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	3.0	60
58	Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , 2019, 72, 30-38.	1.9	60
59	Prostaglandin D Synthase (β -trace) in Healthy Human Sleep. <i>Sleep</i> , 2004, 27, 867-874.	1.1	59
60	Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?. <i>Journal of Neurology</i> , 2009, 256, 3-12.	3.6	57
61	CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis. <i>Neuroscience Letters</i> , 2009, 452, 214-217.	2.1	57
62	The Neurofilament Heavy Chain (NfH^{SMI35}) in the Cerebrospinal Fluid Diagnosis of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 21, 291-295.	1.5	56
63	Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. <i>Journal of Neurology</i> , 2010, 257, 1855-1863.	3.6	56
64	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e446.	6.0	54
65	Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. <i>Annals of Neurology</i> , 2011, 70, 520-520.	5.3	53
66	Biochemical Markers in CSF of ALS Patients. <i>Current Medicinal Chemistry</i> , 2008, 15, 1788-1801.	2.4	52
67	MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. <i>Journal of Neuroinflammation</i> , 2018, 15, 88.	7.2	52
68	The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis. <i>Fluids and Barriers of the CNS</i> , 2015, 12, 12.	5.0	50
69	Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). <i>Neuroscience Letters</i> , 2010, 468, 23-27.	2.1	49
70	A Coding Variant of ANO10, Affecting Volume Regulation of Macrophages, Is Associated with Borrelia Seropositivity. <i>Molecular Medicine</i> , 2015, 21, 26-37.	4.4	49
71	Proteome Analysis of Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis (ALS). <i>Neurochemical Research</i> , 2008, 33, 2358-2363.	3.3	48
72	CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome. <i>Muscle and Nerve</i> , 2009, 40, 42-49.	2.2	48

#	ARTICLE	IF	CITATIONS
73	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015, 77, 447-457.	5.3	48
74	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 841.	9.0	48
75	Lumbar and ventricular CSF protein, leukocytes, and lactate in suspected bacterial CNS infections. <i>Neurology</i> , 1998, 51, 1710-1714.	1.1	47
76	Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. <i>Progress in Neurobiology</i> , 2011, 95, 670-685.	5.7	47
77	Effect of epileptic seizures on the cerebrospinal fluid – A systematic retrospective analysis. <i>Epilepsy Research</i> , 2015, 114, 23-31.	1.6	47
78	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016, 263, 2499-2504.	3.6	46
79	GFAP in early multiple sclerosis: A biomarker for inflammation. <i>Neuroscience Letters</i> , 2017, 657, 166-170.	2.1	45
80	Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 129-143.	3.2	45
81	Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. <i>Movement Disorders</i> , 2010, 25, 1284-1288.	3.9	44
82	Kinetics of Serum Neuron-Specific Enolase and Prolactin in Patients After Single Epileptic Seizures. <i>Epilepsia</i> , 1999, 40, 713-718.	5.1	43
83	Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1998, 155, 44-49.	0.6	42
84	Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome (GBS). <i>Journal of Neuroimmunology</i> , 2007, 185, 190-194.	2.3	40
85	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1202-1214.	3.0	40
86	Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 375-391.	3.2	39
87	Retinal involvement in amyotrophic lateral sclerosis: a study with optical coherence tomography and diffusion tensor imaging. <i>Journal of Neural Transmission</i> , 2016, 123, 281-287.	2.8	39
88	Glatiramer acetate (Copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. <i>Neuroscience Letters</i> , 2000, 289, 205-208.	2.1	38
89	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	38
90	Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2073-2086.	2.3	37

#	ARTICLE	IF	CITATIONS
91	Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2011, 6, e23600.	2.5	36
92	Primary Progressive Multiple Sclerosis: Putting Together the Puzzle. <i>Frontiers in Neurology</i> , 2017, 8, 234.	2.4	36
93	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.1	36
94	Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. <i>Journal of Neuroimmunology</i> , 2009, 217, 95-101.	2.3	35
95	Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. <i>Drug Safety</i> , 2016, 39, 1163-1174.	3.2	35
96	CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. <i>Frontiers in Immunology</i> , 2019, 10, 641.	4.8	34
97	CSF profile in primary progressive multiple sclerosis: Re-exploring the basics. <i>PLoS ONE</i> , 2017, 12, e0182647.	2.5	32
98	Diagnostic biomarkers in tear fluid: from sampling to preanalytical processing. <i>Scientific Reports</i> , 2021, 11, 10064.	3.3	32
99	Intercellular adhesion molecule-1 in cerebrospinal fluid—the evaluation of blood-derived and brain-derived fractions in neurological diseases. <i>Journal of Neuroimmunology</i> , 1998, 87, 156-161.	2.3	31
100	Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial. <i>EClinicalMedicine</i> , 2019, 16, 98-106.	7.1	31
101	Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 17.	6.2	30
102	Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study. <i>Pain</i> , 2020, 161, 787-796.	4.2	29
103	Accumulation and therapeutic modulation of 6-sulfo LacNAc ⁺ dendritic cells in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e33.	6.0	28
104	Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. <i>Neurology</i> , 2005, 64, 1971-1973.	1.1	27
105	Patterns of Th1/Th2 Cytokines Predict Clinical Response in Multiple Sclerosis Patients Treated with Glatiramer Acetate. <i>European Neurology</i> , 2011, 65, 164-169.	1.4	26
106	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTL. <i>Journal of Neural Transmission</i> , 2016, 123, 289-296.	2.8	26
107	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
108	Serum neurofilament light chain. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	25

#	ARTICLE	IF	CITATIONS
109	The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation. <i>Cells</i> , 2020, 9, 842.	4.1	25
110	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019, 266, 386-397.	3.6	24
111	CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	24
112	Inhibition of glutamine synthetase in rabbit pneumococcal meningitis is associated with neuronal apoptosis in the dentate gyrus. , 2000, 30, 11-18.		23
113	2D DIGE of the cerebrospinal fluid proteome in neurological diseases. <i>Expert Review of Proteomics</i> , 2010, 7, 29-38.	3.0	23
114	Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients. <i>Annals of Neurology</i> , 2018, 83, 1032-1036.	5.3	23
115	S1 guidelines -lumbar puncture and cerebrospinal fluid analysis- (abridged and translated version). <i>Neurological Research and Practice</i> , 2020, 2, 8.	2.0	23
116	Erythropoietin in Cerebrospinal Fluid: Age-related Reference Values and Relevance in Neurological Disease. <i>Neurochemical Research</i> , 2007, 32, 1163-1168.	3.3	22
117	Immunoabsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies. <i>Journal of Clinical Medicine</i> , 2020, 9, 2025.	2.4	22
118	Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): Proteome analysis of cerebrospinal fluid. <i>Journal of Neuroimmunology</i> , 2009, 214, 109-112.	2.3	21
119	Cerebrospinal fluid markers of idiopathic intracranial hypertension: Is the renin-angiotensinogen system involved?. <i>Cephalalgia</i> , 2011, 31, 116-121.	3.9	20
120	Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 17565-17588.	4.1	20
121	Expression of the beta-trace protein in human pachymeninx as revealed by in situ hybridization and immunocytochemistry. <i>Journal of Neuroscience Research</i> , 1999, 57, 730-734.	2.9	19
122	Gain-of-function STAT1 mutations are associated with intracranial aneurysms. <i>Clinical Immunology</i> , 2017, 178, 79-85.	3.2	19
123	Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. <i>Frontiers in Neurology</i> , 2019, 10, 1179.	2.4	18
124	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 629-640.	2.6	18
125	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 605-611.	1.9	17
126	The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. <i>Cells</i> , 2021, 10, 3056.	4.1	17

#	ARTICLE	IF	CITATIONS
127	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	5.3	17
128	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. <i>Journal of Neuroinflammation</i> , 2017, 14, 172.	7.2	16
129	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 40-48.	1.9	16
130	Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies. <i>Biomedicines</i> , 2020, 8, 312.	3.2	16
131	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015, 39, 601-608.	1.3	15
132	Diagnosis of cerebral toxoplasmosis by detection of <i>Toxoplasma gondii</i> tachyzoites in cerebrospinal fluid. <i>Journal of Neurology</i> , 2008, 255, 939-941.	3.6	13
133	Biochemical Markers of Autoimmune Diseases of the Nervous System. <i>Current Pharmaceutical Design</i> , 2012, 18, 4556-4563.	1.9	13
134	Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 954-960.	3.6	13
135	Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 298-302.	1.9	12
136	Tau-Proteins as Gender-Specific State Markers in Amnesic Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 93-100.	1.5	11
137	Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands. <i>Electrophoresis</i> , 2015, 36, 355-362.	2.4	11
138	Safety and Tolerability of Plasma Exchange and Immunoabsorption in Neuroinflammatory Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 2874.	2.4	11
139	Is APOE ϵ 4 associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, e728.	6.0	11
140	Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1664.	4.1	11
141	Associations between multiple sclerosis and incidence of heart diseases: Systematic review and meta-analysis of observational studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103279.	2.0	10
142	Varicella-Zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study. <i>Journal of Neurology</i> , 2021, , 1.	3.6	10
143	Cognitive Impairment in Superficial Siderosis of the Central Nervous System: A Case Report. <i>Cerebellum</i> , 2009, 8, 61-63.	2.5	8
144	Communicating Hydrocephalus Following Eosinophilic Meningitis Is Pathogenic for Chronic Viliuisk Encephalomyelitis in Northeastern Siberia. <i>PLoS ONE</i> , 2014, 9, e84670.	2.5	8

#	ARTICLE	IF	CITATIONS
145	Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay. High-Throughput, 2017, 6, 18.	4.4	8
146	Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Cells, 2020, 9, 2543.	4.1	8
147	Automated Analysis of Cerebrospinal Fluid Cells Using Commercially Available Blood Cell Analysis Devicesâ€”A Critical Appraisal. Cells, 2021, 10, 1232.	4.1	8
148	Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis. Journal of Neurology, 2007, 254, 1169-1172.	3.6	7
149	Periventricular white matter lesion and incomplete MRZ reaction in a male patient with anti-N-methyl-D-aspartate receptor encephalitis presenting with dysphoric mania. BMJ Case Reports, 2015, 2015, bcr2014209075-bcr2014209075.	0.5	7
150	Intrathecal immunoglobulin synthesis in patients with symptomatic epilepsy and epilepsy of unknown etiology (â€œcryptogenicâ€™). European Journal of Neurology, 2017, 24, 1188-1190.	3.3	7
151	Epilepsy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 259-266.	1.8	7
152	Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis. Clinica Chimica Acta, 2019, 498, 148-153.	1.1	7
153	Genetic determinants of the humoral immune response in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e827.	6.0	7
154	Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. BMC Neurology, 2020, 20, 227.	1.8	6
155	Ongoing challenges in unravelling the association between COVID-19 and Guillain-BarrÃ© syndrome. Brain, 2021, 144, e44-e44.	7.6	6
156	Immunological and histochemical analyses of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Acta Neuropsychiatrica, 2009, 21, 51-57.	2.1	4
157	6â€šulpho LacNAc⁺ dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system. Neuropathology and Applied Neurobiology, 2016, 42, 394-398.	3.2	4
158	Drug-induced liver injury associated with the biosimilar glatiramer acetate (CliftÃ©). Multiple Sclerosis and Related Disorders, 2020, 40, 101948.	2.0	4
159	Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway. Annals of Clinical and Translational Neurology, 2021, 8, 2228-2234.	3.7	4
160	CIS case studies. Journal of the Neurological Sciences, 2009, 287, S7-S10.	0.6	3
161	Tick-Borne Encephalitis: A Differential Pattern of Intrathecal Humoral Immune Response and Inflammatory Cell Composition Compared with Other Viral CNS Infections. Cells, 2020, 9, 2169.	4.1	3
162	A one-year longitudinal evaluation of cerebrospinal fluid and blood neurochemical markers in a patient with cryptococcal meningitis complicated by ischemic stroke.. Journal of the Neurological Sciences, 2022, 432, 120090.	0.6	3

#	ARTICLE	IF	CITATIONS
163	Cognitive Reserve in Alzheimer's Dementia: Diagnostic Accuracy of a Testing-the-Limits Paradigm. Journal of Alzheimer's Disease, 2016, 52, 519-528.	2.6	2
164	Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis. Expert Review of Molecular Diagnostics, 2016, 16, 1353-1356.	3.1	2
165	Rare indications of IVIG therapy in neurological diseases based on case reports and small studies. Journal of Neurology, 2006, 253, v66-v69.	3.6	1
166	Unsolved Medical Problems: Blood-brain barrier in neurodegenerative diseases: perspectives for Nanomedicine. European Journal of Nanomedicine, 2009, 2, .	0.6	1
167	Comprehensive microRNA expression profiling in cerebrospinal fluid distinguishes between neurological disease classes. Neuropathology and Applied Neurobiology, 2019, 45, 318-323.	3.2	1
168	Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers and cognitive performance. Proceedings of the Nutrition Society, 2020, 79, .	1.0	1
169	Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110225.	3.5	1
170	The Sexual Dimorphism in Cerebrospinal Fluid Protein Content Does Not Affect Intrathecal IgG Synthesis in Multiple Sclerosis. Journal of Personalized Medicine, 2022, 12, 977.	2.5	1
171	Identification of disease-related biomarkers by proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome. Future Neurology, 2007, 2, 629-631.	0.5	0
172	ZNS und Nervensystem. , 2009, , 321-349.		0
173	Marker des Liquor cerebrospinalis und des Blutes im Überblick. , 2015, , 123-135.		0
174	Erweiterte Liquor- und Blutanalyse. , 2018, , 123-134.		0